Learn about Research & Clinical Trials

Detection of Early Idiopathic Pulmonary Fibrosis

Study Purpose

The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 40 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria for Control Subjects:

  • - Subjects ≥ 18 y.
o.
  • - No lung diseases.
Inclusion Criteria for IPF Patients:
  • - Informed consent.
  • - Subjects ≥ 40 y.
o.
  • - Naive patients with no IPF treatment.
  • - IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria.
Inclusion Criteria for non-IPF ILD Patients:
  • - Informed consent.
  • - Subjects ≥ 18 y.
o.
  • - ILD diagnosis.
Exclusion Criteria for control subjects, IPF and non-IPF ILD patients:
  • - HIV.
  • - Hepatitis B.
  • - Hepatitis C.
- Pregnant or lactating women

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03457935
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Temple University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Idiopathic Pulmonary Fibrosis
Arms & Interventions

Arms

: Control

No lung diseases

: Non-IPF ILD

non-IPF ILD diagnosis

: IPF

Naive patients with no IPF treatment

Interventions

Other: - blood samples

Blood samples

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Temple University, Philadelphia, Pennsylvania

Status

Recruiting

Address

Temple University

Philadelphia, Pennsylvania, 19140

Site Contact

Beata Kosmider, MS, PhD

beata.kosmider@temple.edu

215-707-9084